H.I.G. Capital is exploring the sale of Taconic Biosciences, a Rensselaer, New York-based pre-clinical research development company, three sources tell Sarah.
What's happening: A Baird-run sale process recently kicked off, sources say, with first-round bids collected earlier this week.
The company is marketing approximately $30 million of EBITDA, some of the people say.
